Literature DB >> 24450327

Gallium-68 DOTATOC PET/CT in vivo characterization of somatostatin receptor expression in the prostate.

Mila V Todorović-Tirnanić1, Milan M Gajić, Vladimir B Obradović, Richard P Baum.   

Abstract

AIM: The aim was to investigate somatostatin receptor (sstr) expression in normal prostate by determining the maximum standardized uptake value (SUVmax) of (68)Ga-DOTATOC PET/CT in neuroendocrine tumor (NET) patients, without NET involvement of the prostate gland, for establishing the reference standard.
METHODS: Sixty-four NET patients underwent (68)Ga-DOTATOC PET/CT. SUVmax of the prostate gland, normal liver, testes, and gluteus muscles were evaluated. The prostate gland size was measured. Statistical analysis was performed using dedicated software (SPSS13).
RESULTS: Mean/median (68)Ga-DOTATOC SUVmax values were as follows: normal prostate 2.6 ± 0.0, slightly enlarged prostate 4.2 ± 1.6, prostatic hypertrophy 4.9 ± 1.6, prostatic hyperplasia 5.0 ± 1.5, prostate cancer 9.5 ± 2.1, normal liver 7.3 ± 1.8, testes 1.8 ± 0.5, and gluteus 1.0 ± 0.2. The normal prostate gland had three times less sstr expression than normal liver tissue. Strong correlation was found between patient age and sstr expression in prostate/prostate size. No significant difference existed in sstr expression between prostatic hypertrophy and hyperplasia. Much higher sstr expression was found in prostatic cancer compared with normal prostate.
CONCLUSION: (68)Ga-DOTATOC PET/CT defines the baseline sstr uptake in prostate not affected by NET (significantly lower than in the liver). Higher values were established in prostatic hyperplasia and hypertrophy. Only concomitant prostate cancer was associated with higher SUVmax in comparison with non-neoplastic liver.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24450327      PMCID: PMC3961796          DOI: 10.1089/cbr.2013.1570

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  30 in total

Review 1.  Rationale for the use of radiolabelled peptides in diagnosis and therapy.

Authors:  K P Koopmans; A W J M Glaudemans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

2.  Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?

Authors:  Daniel Storch; Martin Béhé; Martin A Walter; Jianhua Chen; Pia Powell; Renata Mikolajczak; Helmut R Mäcke
Journal:  J Nucl Med       Date:  2005-09       Impact factor: 10.057

3.  PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.

Authors:  H J Wester; M Schottelius; K Scheidhauer; G Meisetschläger; M Herz; F C Rau; J C Reubi; M Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-11-05       Impact factor: 9.236

Review 4.  Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.

Authors:  Jean Claude Reubi; Beatrice Waser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-18       Impact factor: 9.236

5.  99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.

Authors:  C Decristoforo; S J Mather; W Cholewinski; E Donnemiller; G Riccabona; R Moncayo
Journal:  Eur J Nucl Med       Date:  2000-09

Review 6.  Nuclear medicine imaging of neuroendocrine tumours.

Authors:  E Bombardieri; M Maccauro; E De Deckere; G Savelli; A Chiti
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

Review 7.  Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status.

Authors:  H Bonkhoff
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

8.  Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions.

Authors:  V Prasad; R P Baum
Journal:  Q J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 2.346

Review 9.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

10.  Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.

Authors:  M de Jong; W H Bakker; E P Krenning; W A Breeman; M E van der Pluijm; B F Bernard; T J Visser; E Jermann; M Béhé; P Powell; H R Mäcke
Journal:  Eur J Nucl Med       Date:  1997-04
View more
  4 in total

1.  Demonstration of focal physiologic in-vivo somatostatin receptor expression in the caput epididymis of the testes on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE post-therapy whole body scintigraphy.

Authors:  Ashwin Singh Parihar; Apurva Sood; Ashwani Sood; Ajay Gulati; Bhagwant Rai Mittal
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020

2.  A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of 68Ga-DOTATOC in healthy volunteers.

Authors:  Shadi A Esfahani; Stephanie Salcedo; Pedram Heidari; Onofrio A Catalano; Rachel Pauplis; Jacob Hesterman; James F Kronauge; Umar Mahmood
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-04-15

3.  Improving PET Quantification of Small Animal [68Ga]DOTA-Labeled PET/CT Studies by Using a CT-Based Positron Range Correction.

Authors:  Jacobo Cal-Gonzalez; Juan José Vaquero; Joaquín L Herraiz; Mailyn Pérez-Liva; María Luisa Soto-Montenegro; Santiago Peña-Zalbidea; Manuel Desco; José Manuel Udías
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

Review 4.  A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer.

Authors:  Ephraim E Parent; Adam M Kase
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.